{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:35:33Z","timestamp":1791725733494,"version":"4.3.4"},"reference-count":155,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT &amp; Future Planning","award":["NRF-2021R1F1A1060378"],"award-info":[{"award-number":["NRF-2021R1F1A1060378"]}]},{"name":"Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education","award":["NRF-2020R1A6A1A03043708"],"award-info":[{"award-number":["NRF-2020R1A6A1A03043708"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Nose-to-brain drug delivery has been of great interest for the treatment of many central nervous system (CNS) diseases and psychiatric disorders over past decades. Several nasally administered formulations have been developed to circumvent the blood-brain barrier and directly deliver drugs to the CNS through the olfactory and trigeminal pathways. However, the nasal mucosa\u2019s drug absorption is insufficient and the volume of the nasal cavity is small, which, in combination, make nose-to-brain drug delivery challenging. These problems could be minimized using formulations based on solid lipid nanoparticles (SLNs) or nanostructured lipid carriers (NLCs), which are effective nose-to-brain drug delivery systems that improve drug bioavailability by increasing drug solubility and permeation, extending drug action, and reducing enzymatic degradation. Various research groups have reported in vivo pharmacokinetics and pharmacodynamics of SLNs and NLCs nose-to-brain delivery systems. This review was undertaken to provide an overview of these studies and highlight research performed on SLN and NLC-based formulations aimed at improving the treatment of CNS diseases such neurodegenerative diseases, epilepsy, and schizophrenia. We discuss the efficacies and brain targeting efficiencies of these formulations based on considerations of their pharmacokinetic parameters and toxicities, point out some gaps in current knowledge, and propose future developmental targets.<\/jats:p>","DOI":"10.3390\/pharmaceutics14030572","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T20:40:02Z","timestamp":1646599202000},"page":"572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-4399","authenticated-orcid":false,"given":"Thi-Thao-Linh","family":"Nguyen","sequence":"first","affiliation":[{"name":"College of Pharmacy, Gachon University, 191 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Joo","family":"Maeng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Gachon University, 191 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hong, S.-S., Oh, K.T., Choi, H.-G., and Lim, S.-J. (2019). Liposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11100540"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jddst.2017.09.022","article-title":"Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders","volume":"43","author":"Md","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Achar, A., Myers, R., and Ghosh, C. (2021). Drug Delivery Challenges in Brain Disorders across the Blood\u2014Brain Barrier: Novel Methods and Future Considerations for Improved Therapy. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121834"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood\u2013brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital. J. Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3\u201325.1","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejpb.2022.02.004","article-title":"Is oral lipid-based delivery for drug targeting to the brain feasible?","volume":"172","author":"Brookes","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","article-title":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","volume":"295","author":"Costa","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bahadur, S., Pardhi, D.M., Rautio, J., Rosenholm, J.M., and Pathak, K. (2020). Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12121230"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Maaz, A., Blagbrough, I.S., and De Bank, P.A. (2021). In Vitro Evaluation of Nasal Aerosol Depositions: An Insight for Direct Nose to Brain Drug Delivery. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071079"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Riccardi, C., Napolitano, F., Montesarchio, D., Sampaolo, S., and Melone, M.A.B. (2021). Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111897"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lee, D., and Minko, T. (2021). Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122049"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/IJN.S247935","article-title":"Primary Studies on Construction and Evaluation of Ion-Sensitive in situ Gel Loaded with Paeonol-Solid Lipid Nanoparticles for Intranasal Drug Delivery","volume":"15","author":"Sun","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejps.2016.05.002","article-title":"Intranasal haloperidol-loaded miniemulsions for brain targeting: Evaluation of locomotor suppression and in-vivo biodistribution","volume":"92","author":"Ibrahim","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2016.02.038","article-title":"Identifying lipidic emulsomes for improved oxcarbazepine brain targeting: In vitro and rat in vivo studies","volume":"503","author":"Soliman","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/jpet.119.258152","article-title":"Nose-to-Brain Delivery","volume":"370","author":"Wang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S1359-6446(02)02529-1","article-title":"Nasal drug delivery: New developments and strategies","volume":"7","author":"Illum","year":"2002","journal-title":"Drug Discov. Today"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejpb.2021.07.015","article-title":"Dopamine-loaded lipid based nanocarriers for intranasal administration of the neurotransmitter: A comparative study","volume":"167","author":"Trapani","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bonferoni, M.C., Rassu, G., Gavini, E., Sorrenti, M., Catenacci, L., and Giunchedi, P. (2020). Nose-to-Brain Delivery of Antioxidants as a Potential Tool for the Therapy of Neurological Diseases. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12121246"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Musumeci, T., Bonaccorso, A., and Puglisi, G. (2019). Epilepsy Disease and Nose-to-Brain Delivery of Polymeric Nanoparticles: An Overview. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11030118"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jnaidi, R., Almeida, A.J., and Gon\u00e7alves, L.M. (2020). Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Smart Drug Delivery Systems in the Treatment of Glioblastoma Multiforme. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090860"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"de Barros, C.T., Rios, A.C., Alves, T.F.R., Batain, F., Crescencio, K.M.M., Lopes, L.J., Zieli\u0144ska, A., Severino, P., Mazzola, P., and Souto, E.B. (2020). Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21175974"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/nbm.2932","article-title":"Manganese-enhanced MRI of rat brain based on slow cerebral delivery of manganese(II) with silica-encapsulated MnxFe1\u2013xO nanoparticles","volume":"26","author":"Chen","year":"2013","journal-title":"NMR Biomed."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7150\/ntno.31164","article-title":"Magnetic Heating Stimulated Cargo Release with Dose Control using Multifunctional MR and Thermosensitive Liposome","volume":"3","author":"Ray","year":"2019","journal-title":"Nanotheranostics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12249-018-1213-y","article-title":"Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies","volume":"20","author":"Gadhave","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"120881","DOI":"10.1016\/j.ijpharm.2021.120881","article-title":"Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson\u2019s disease","volume":"606","author":"Uppuluri","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1039\/C5RA19793G","article-title":"Intranasal delivery of asenapine loaded nanostructured lipid carriers: Formulation, characterization, pharmacokinetic and behavioural assessment","volume":"6","author":"Singh","year":"2016","journal-title":"RSC Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ijbiomac.2017.11.031","article-title":"Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: Pharmacokinetic and teratogenic assessment","volume":"108","author":"Singh","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.2174\/1381612824666171128105305","article-title":"Intranasal Lipid Nanoparticles for the Treatment of Neurodegenerative Diseases","volume":"23","author":"Cunha","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2174\/1389200221666200719003304","article-title":"Nanostructured Lipid Carriers (NLCs): Nose-to-Brain Delivery and Theranostic Application","volume":"21","author":"Ahmad","year":"2020","journal-title":"Curr. Drug Metab."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Costa, C.P., Barreiro, S., Moreira, J.N., Silva, R., Almeida, H., Sousa Lobo, J.M., and Silva, A.C. (2021). In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN). Pharmaceuticals, 14.","DOI":"10.3390\/ph14080711"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","article-title":"Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies","volume":"11","author":"Costa","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: Mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1039\/C6NR07581A","article-title":"Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles","volume":"9","author":"Ahmad","year":"2017","journal-title":"Nanoscale"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nair, S.C., Vinayan, K.P., and Mangalathillam, S. (2021). Nose to Brain Delivery of Phenytoin Sodium Loaded Nano Lipid Carriers: Formulation, Drug Release, Permeation and In Vivo Pharmacokinetic Studies. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101640"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.drudis.2018.01.005","article-title":"An update on the role of nanovehicles in nose-to-brain drug delivery","volume":"23","author":"Feng","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s13346-012-0110-2","article-title":"SLN approach for nose-to-brain delivery of alprazolam","volume":"2","author":"Singh","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"G\u00e4nger, S., and Schindowski, K. (2018). Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10030116"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","article-title":"A review of intranasal formulations for the treatment of seizure emergencies","volume":"237","author":"Kapoor","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: Production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014A review of the state of the art","volume":"50","author":"Gohla","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.addr.2003.12.002","article-title":"Solid lipid nanoparticles for parenteral drug delivery","volume":"56","author":"Wissing","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Tan, S.L.J., and Billa, N. (2021). Improved Bioavailability of Poorly Soluble Drugs through Gastrointestinal Muco-Adhesion of Lipid Nanoparticles. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111817"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Nguyen, T.-T.-L., Duong, V.-A., and Maeng, H.-J. (2021). Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071103"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"580118","DOI":"10.3389\/fchem.2021.580118","article-title":"Lipid Nanoparticles as Carriers for Bioactive Delivery","volume":"9","author":"Dhiman","year":"2021","journal-title":"Front. Chem."},{"key":"ref_47","first-page":"72","article-title":"The Tiny Big World of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: An Updated Review","volume":"39","author":"Mohamed","year":"2021","journal-title":"J. Microencapsul."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"120100","DOI":"10.1016\/j.ijpharm.2020.120100","article-title":"Solid lipid nanoparticle-loaded mucoadhesive buccal films\u2014Critical quality attributes and in vitro safety & efficacy","volume":"592","author":"Tzanova","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Qushawy, M., Prabahar, K., Abd-Alhaseeb, M., Swidan, S., and Nasr, A. (2019). Preparation and Evaluation of Carbamazepine Solid Lipid Nanoparticle for Alleviating Seizure Activity in Pentylenetetrazole-Kindled Mice. Molecules, 24.","DOI":"10.3390\/molecules24213971"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejpb.2008.09.003","article-title":"Lipid nanoparticles for parenteral delivery of actives","volume":"71","author":"Joshi","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jddst.2019.101185","article-title":"Nanostructured lipid carriers containing ondansetron hydrochloride by cold high-pressure homogenization method: Preparation, characterization, and pharmacokinetic evaluation","volume":"53","author":"Duong","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/03639045.2019.1711388","article-title":"Preparation, optimization, and in-vitro characterization of \u03b1-tocopherol-loaded solid lipid nanoparticles (SLNs)","volume":"46","author":"Nasiri","year":"2020","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Duong, V.-A., Nguyen, T.-T.-L., and Maeng, H.-J. (2020). Preparation of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Drug Delivery and the Effects of Preparation Parameters of Solvent Injection Method. Molecules, 25.","DOI":"10.3390\/molecules25204781"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","article-title":"Nanostructured lipid matrices for improved microencapsulation of drugs","volume":"242","author":"Radtke","year":"2002","journal-title":"Int. J. Pharm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11095-019-2672-x","article-title":"Preparation of Ondansetron Hydrochloride-Loaded Nanostructured Lipid Carriers Using Solvent Injection Method for Enhancement of Pharmacokinetic Properties","volume":"36","author":"Duong","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"104475","DOI":"10.1016\/j.dib.2019.104475","article-title":"Data on optimization and drug release kinetics of nanostructured lipid carriers containing ondansetron hydrochloride prepared by cold high-pressure homogenization method","volume":"26","author":"Duong","year":"2019","journal-title":"Data Brief"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jconrel.2021.04.020","article-title":"Intranasal artesunate-loaded nanostructured lipid carriers: A convenient alternative to parenteral formulations for the treatment of severe and cerebral malaria","volume":"334","author":"Agbo","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Abourehab, M.A.S., Khames, A., Genedy, S., Mostafa, S., Khaleel, M.A., Omar, M.M., and El Sisi, A.M. (2021). Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040581"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.2174\/1381612822666160720163656","article-title":"Strategies that Target Tight Junctions for Enhanced Drug Delivery","volume":"22","author":"Posadas","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/10717544.2017.1357148","article-title":"Agomelatine-based in situ gels for brain targeting via the nasal route: Statistical optimization, in vitro, and in vivo evaluation","volume":"24","author":"Fatouh","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijpharm.2014.07.025","article-title":"Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route","volume":"473","author":"Gabal","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.044","article-title":"Stimuli-responsive In situ gelling system for nose-to-brain drug delivery","volume":"327","author":"Agrawal","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1567201815666181011121750","article-title":"Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study","volume":"16","author":"Qureshi","year":"2019","journal-title":"Curr. Drug Deliv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102114","DOI":"10.1016\/j.jddst.2020.102114","article-title":"Intranasal delivery of polymer-anchored lipid nanoconstructs of artemether-lumefantrine in Plasmodium berghei ANKA murine model","volume":"61","author":"Kaur","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biopha.2017.07.067","article-title":"Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: In-vivo pharmacokinetic and toxicity study","volume":"94","author":"Pokharkar","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/1061186X.2010.523787","article-title":"Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route","volume":"19","author":"Patel","year":"2011","journal-title":"J. Drug Target."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2147\/DDDT.S102500","article-title":"Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: Formulation, optimization and in vivo pharmacokinetics","volume":"11","author":"Fatouh","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","article-title":"Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer\u2019s disease","volume":"92","author":"Muntimadugu","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"102533","DOI":"10.1016\/j.jddst.2021.102533","article-title":"Clozapine loaded nanostructured lipid carriers engineered for brain targeting via nose-to-brain delivery: Optimization and in vivo pharmacokinetic studies","volume":"64","author":"Patel","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.xphs.2020.04.007","article-title":"Coated Lipidic Nanoparticles as a New Strategy for Enhancing Nose-to-Brain Delivery of a Hydrophilic Drug Molecule","volume":"109","author":"Salem","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1039\/C5RA19113K","article-title":"Nose to brain delivery of astaxanthin-loaded solid lipid nanoparticles: Fabrication, radio labeling, optimization and biological studies","volume":"6","author":"Srivastava","year":"2016","journal-title":"RSC Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpharm.2013.11.038","article-title":"Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood","volume":"461","author":"Kumar","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2014.05.004","article-title":"Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug","volume":"470","author":"Alam","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ijbiomac.2020.11.047","article-title":"Nose-to-brain delivery of teriflunomide-loaded lipid-based carbopol-gellan gum nanogel for glioma: Pharmacological and in vitro cytotoxicity studies","volume":"167","author":"Gadhave","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s13204-018-0909-3","article-title":"Neutropenia and leukopenia protective intranasal olanzapine-loaded lipid-based nanocarriers engineered for brain delivery","volume":"9","author":"Gadhave","year":"2019","journal-title":"Appl. Nanosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","article-title":"Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration","volume":"134","author":"Gartziandia","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"102164","DOI":"10.1016\/j.jddst.2020.102164","article-title":"Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: Formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation","volume":"61","author":"Yasir","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_78","first-page":"5411","article-title":"Nanostructured lipid carriers (NLCs)-based intranasal Drug Delivery System of Tenofovir disoproxil fumerate (TDF) for brain targeting","volume":"13","author":"Sarma","year":"2020","journal-title":"Res. J. Pharm. Technol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"150","DOI":"10.34172\/apb.2021.016","article-title":"Development of Carbamazepine Nanostructured Lipid Carrier Loaded Thermosensitive Gel for Intranasal Delivery","volume":"11","author":"Deshkar","year":"2021","journal-title":"Adv. Pharm. Bull."},{"key":"ref_80","first-page":"363","article-title":"Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: In vivo pharmacodynamic studies using rat electroshock model","volume":"6","author":"Eskandari","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/17425247.2014.945416","article-title":"Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: In vitro characterization and in vivo efficacy in epilepsy","volume":"12","author":"Alam","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/21691401.2016.1160407","article-title":"Development and characterization of embelin-loaded nanolipid carriers for brain targeting","volume":"45","author":"Sharma","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.xphs.2018.04.007","article-title":"Superparamagnetic Iron Oxide\u2013Loaded Lipid Nanocarriers Incorporated in Thermosensitive In Situ Gel for Magnetic Brain Targeting of Clonazepam","volume":"107","author":"Abbas","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1049\/iet-nbt.2019.0156","article-title":"In-vitro and in-vivo evaluation of chitosan-based thermosensitive gel containing lorazepam NLCs for the treatment of status epilepticus","volume":"14","author":"Taymouri","year":"2020","journal-title":"IET Nanobiotechnol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s13346-018-0540-6","article-title":"In situ nanostructured hydrogel of resveratrol for brain targeting: In vitro-in vivo characterization","volume":"8","author":"Rajput","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jddst.2019.01.040","article-title":"Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: Formulation, optimization and in vivo characterization","volume":"51","author":"Rajput","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_87","first-page":"4","article-title":"Fabrication of an ion-sensitive in situ gel loaded with nanostructured lipid carrier for nose to brain delivery of donepezil","volume":"12","author":"Butani","year":"2018","journal-title":"Asian J. Pharm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1016\/j.xphs.2017.08.024","article-title":"Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics","volume":"106","author":"Wavikar","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jddst.2018.11.021","article-title":"Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model","volume":"49","author":"Anand","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"111838","DOI":"10.1016\/j.colsurfb.2021.111838","article-title":"Systematically designed chitosan-coated solid lipid nanoparticles of ferulic acid for effective management of Alzheimer\u2019s disease: A preclinical evidence","volume":"205","author":"Saini","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"134","DOI":"10.9734\/jpri\/2021\/v33i45A32725","article-title":"Preclinical Screening of Antidepressant Activity of Formulated Sertraline Hydrochloride-Loaded Solid Lipid Nanoparticles in Rats","volume":"33","author":"Hangargekar","year":"2021","journal-title":"J. Pharm. Res. Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jpsychires.2012.05.014","article-title":"Intranasal administration of nanostructured lipid carriers containing CNS acting drug: Pharmacodynamic studies and estimation in blood and brain","volume":"46","author":"Alam","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejpb.2020.04.011","article-title":"QbD-driven development of intranasal lipid nanoparticles for depression treatment","volume":"153","author":"Vitorino","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12035-017-0728-7","article-title":"Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson\u2019s Disease","volume":"55","author":"Hernando","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1166\/jbn.2016.2313","article-title":"Intranasal Administration of Chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson\u2019s Disease","volume":"12","author":"Gartziandia","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10717544.2012.752421","article-title":"Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: Application of factorial design approach","volume":"20","author":"Pardeshi","year":"2013","journal-title":"Drug Deliv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2174\/1567201818666210510173524","article-title":"Appraisal of Nano-lipidic Astaxanthin Cum Thermoreversible Gel and its Efficacy in Haloperidol Induced Parkinsonism","volume":"18","author":"Gautam","year":"2021","journal-title":"Curr. Drug Deliv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/1871524919666181126124846","article-title":"Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson\u2019s Disease","volume":"19","author":"Mishra","year":"2019","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ijpharm.2018.07.014","article-title":"A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation","volume":"548","author":"Youssef","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/03639045.2019.1576724","article-title":"Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: Optimization and in vivo studies","volume":"45","author":"Gadhave","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/10717544.2013.822945","article-title":"Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood","volume":"20","author":"Alam","year":"2013","journal-title":"Drug Deliv."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e16047","DOI":"10.1590\/s2175-97902017000216047","article-title":"Development of a new HPLC method for in vitro and in vivo studies of haloperidol in solid lipid nanoparticles","volume":"53","author":"Yasir","year":"2017","journal-title":"Braz. J. Pharm. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.apsb.2014.10.005","article-title":"Solid lipid nanoparticles for nose to brain delivery of haloperidol: In vitro drug release and pharmacokinetics evaluation","volume":"4","author":"Yasir","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/1061186X.2012.716845","article-title":"Nanostructured lipid carriers system: Recent advances in drug delivery","volume":"20","author":"Iqbal","year":"2012","journal-title":"J. Drug Target."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jconrel.2008.02.007","article-title":"Design and production of nanoparticles formulated from nano-emulsion templates\u2014A review","volume":"128","author":"Anton","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11051-017-4042-0","article-title":"Lipid-based nanoparticles as drug delivery system for paclitaxel in breast cancer treatment","volume":"19","author":"Carneiro","year":"2017","journal-title":"J. Nanoparticle Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/10717544.2014.885999","article-title":"Optimization of artemether-loaded NLC for intranasal delivery using central composite design","volume":"22","author":"Jain","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.5958\/0974-360X.2018.00523.1","article-title":"Formulation and evaluation of glyceryl behenate based solid lipid nanoparticles for the delivery of donepezil to brain through nasal route","volume":"11","author":"Yasir","year":"2018","journal-title":"Res. J. Pharm. Technol."},{"key":"ref_110","first-page":"1838","article-title":"Solid lipid nanoparticles for nose to brain delivery of donepezil: Formulation, optimization by Box\u2013Behnken design, in vitro and in vivo evaluation","volume":"46","author":"Yasir","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"751321","DOI":"10.3389\/fphar.2021.751321","article-title":"Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro\/In Vivo Evaluation","volume":"12","author":"Silva","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"111076","DOI":"10.1016\/j.colsurfb.2020.111076","article-title":"Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation","volume":"193","author":"Sayed","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.colsurfb.2014.06.037","article-title":"Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron HCl using Delonix regia gum as a natural mucoadhesive polymer","volume":"122","author":"Devkar","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1021\/acs.molpharmaceut.1c00276","article-title":"Synchronizing In Silico, In Vitro, and In Vivo Studies for the Successful Nose to Brain Delivery of an Anticancer Molecule","volume":"18","author":"Metwally","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/jphp.13316","article-title":"Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: Preparation, optimization, characterization and pharmacokinetic evaluation","volume":"72","author":"Masjedi","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1021\/acs.molpharmaceut.6b00586","article-title":"Brain Targeting of Temozolomide via the Intranasal Route Using Lipid-Based Nanoparticles: Brain Pharmacokinetic and Scintigraphic Analyses","volume":"13","author":"Khan","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_117","first-page":"31","article-title":"Ziprasidone hydrochloride loaded nanostructured lipid carriers (NLCS) for intranasal delivery: Optimization and in vivo studies","volume":"12","author":"Praveen","year":"2020","journal-title":"Int. J. Appl. Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"102939","DOI":"10.1016\/j.jddst.2021.102939","article-title":"Intranasal delivery of chitosan decorated nanostructured lipid carriers of Buspirone for brain targeting: Formulation development, optimization and In-Vivo preclinical evaluation","volume":"67","author":"Noorulla","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12668-020-00821-2","article-title":"Augmented Brain Delivery of Cinnarizine Through Nanostructured Lipid Carriers Loaded in situ Gel: In vitro and Pharmacokinetic Evaluation","volume":"11","author":"Tripathi","year":"2021","journal-title":"BioNanoScience"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3109\/10717544.2014.975382","article-title":"Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: Design, characterization, and in vivo study","volume":"23","author":"Madane","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.2147\/IJN.S258791","article-title":"Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin","volume":"15","author":"Fahmy","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.xphs.2019.05.001","article-title":"Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies","volume":"108","author":"Jazuli","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40199-019-00304-0","article-title":"Application of computational tools for the designing of Oleuropein loaded nanostructured lipid carrier for brain targeting through nasal route","volume":"27","author":"Palagati","year":"2019","journal-title":"DARU J. Pharm. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2217\/nnm-2018-0417","article-title":"Improved brain delivery of pueraria flavones via intranasal administration of borneol-modified solid lipid nanoparticles","volume":"14","author":"Wang","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_125","first-page":"12","article-title":"Direct brain targeted nanostructured lipid carriers for sustained release of schizophrenic drug: Formulation, characterization and pharmacokinetic studies","volume":"9","author":"Sivadasu","year":"2020","journal-title":"Brain"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1016\/j.matpr.2015.10.067","article-title":"Preparation and Characterization of Rizatriptan Benzoate Loaded Solid Lipid Nanoparticles for Brain Targeting","volume":"2","author":"Singh","year":"2015","journal-title":"Mater. Today Proc."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/10667857.2019.1674522","article-title":"Improved brain pharmacokinetics following intranasal administration of N,N,N-trimethyl chitosan tailored mucoadhesive NLCs","volume":"35","author":"Pardeshi","year":"2020","journal-title":"Mater. Technol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5984014","DOI":"10.1155\/2017\/5984014","article-title":"Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability","volume":"2017","author":"Gupta","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/03639045.2019.1593439","article-title":"Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer\u2019s disease using Box-Behnken design","volume":"45","author":"Jojo","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.msec.2014.12.012","article-title":"Cannabinoid antagonist in nanostructured lipid carriers (NLCs): Design, characterization and in vivo study","volume":"48","author":"Esposito","year":"2015","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2017.04.011","article-title":"Nanoformulations for dimethyl fumarate: Physicochemical characterization and in vitro\/in vivo behavior","volume":"115","author":"Esposito","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"120428","DOI":"10.1016\/j.ijpharm.2021.120428","article-title":"Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose","volume":"599","author":"Hasan","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_133","first-page":"17590","article-title":"Preparation and brain delivery of nasal solid lipid nanoparticles of quetiapine fumarate in situ gel in rat model of schizophrenia","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jconrel.2020.02.033","article-title":"Nasal administration of nanoencapsulated geraniol\/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson\u2019s disease","volume":"321","author":"Truzzi","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"105060","DOI":"10.1016\/j.chemphyslip.2021.105060","article-title":"Intranasal solid lipid nanoparticles for management of pain: A full factorial design approach, characterization & Gamma Scintigraphy","volume":"236","author":"Khanna","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s10856-012-4702-7","article-title":"Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: Development, optimization and evaluation","volume":"23","author":"Joshi","year":"2012","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3109\/10717544.2014.880860","article-title":"Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington\u2019s disease","volume":"22","author":"Bhatt","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"86","DOI":"10.22159\/ijap.2020v12i2.36812","article-title":"Zolmitriptan Brain targeting via intranasal route using solid lipid nanoparticles for migraine therapy: Formulation, Characterization, in-vitro and In-vivo Assessment","volume":"10","author":"Mostafa","year":"2020","journal-title":"Int. J. Appl. Pharm."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"105698","DOI":"10.1016\/j.ejps.2020.105698","article-title":"Mucoadhesive nanostructured lipid carriers as a cannabidiol nasal delivery system for the treatment of neuropathic pain","volume":"159","author":"Matarazzo","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"110446","DOI":"10.1016\/j.colsurfb.2019.110446","article-title":"Development of nose-to-brain delivery of ketoconazole by nanostructured lipid carriers against cryptococcal meningoencephalitis in mice","volume":"183","author":"Du","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10544-017-0188-x","article-title":"Lipid nanoparticles for administration of poorly water soluble neuroactive drugs","volume":"19","author":"Esposito","year":"2017","journal-title":"Biomed. Microdevices"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-5173(98)00367-6","article-title":"Evaluation of the clearance characteristics of bioadhesive systems in humans","volume":"178","author":"Soane","year":"1999","journal-title":"Int. J. Pharm."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jfda.2014.01.012","article-title":"Neurotoxicity of nanoscale materials","volume":"22","author":"Karmakar","year":"2014","journal-title":"J. Food Drug Anal."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","article-title":"Nasal mucociliary clearance as a factor in nasal drug delivery","volume":"29","author":"Marttin","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejpb.2015.05.019","article-title":"Intranasal delivery of dopamine to the striatum using glycol chitosan\/sulfobutylether-\u03b2-cyclodextrin based nanoparticles","volume":"94","author":"Trapani","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"119829","DOI":"10.1016\/j.ijpharm.2020.119829","article-title":"Synthesis and characterization of novel chitosan-dopamine or chitosan-tyrosine conjugates for potential nose-to-brain delivery","volume":"589","author":"Cassano","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Sonvico, F., Clementino, A., Buttini, F., Colombo, G., Pescina, S., Stanis\u00e7uaski Guterres, S., Raffin Pohlmann, A., and Nicoli, S. (2018). Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting. Pharmaceutics, 10.","DOI":"10.20944\/preprints201802.0077.v1"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Trapani, A., Cometa, S., De Giglio, E., Corbo, F., Cassano, R., Di Gioia, M.L., Trombino, S., Hossain, M.N., Di Gioia, S., and Trapani, G. (2022). Novel Nanoparticles Based on N,O-Carboxymethyl Chitosan-Dopamine Amide Conjugate for Nose-to-Brain Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010147"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.progpolymsci.2014.07.010","article-title":"Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review","volume":"39","author":"Sosnik","year":"2014","journal-title":"Prog. Polym. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ijpharm.2017.11.071","article-title":"Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis","volume":"536","author":"Vieira","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejpb.2018.02.010","article-title":"Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles","volume":"127","author":"Trotta","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.drudis.2019.10.005","article-title":"Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: Status quo and outlook","volume":"25","author":"Sabir","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Bors","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2133\/dmpk.DMPK-10-RG-049","article-title":"Lack of a Primary Physicochemical Determinant in the Direct Transport of Drugs to the Brain after Nasal Administration in Rats: Potential Involvement of Transporters in the Pathway","volume":"25","author":"Lee","year":"2010","journal-title":"Drug Metab. Pharmacokinet."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/3\/572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:32:34Z","timestamp":1760135554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/3\/572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,5]]},"references-count":155,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["pharmaceutics14030572"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14030572","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,5]]}}}